Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact Bococizumab exits the PCSK9 stage: A response from PCSK9 Forum Editors Pfizer announced on Tuesday, 1st November that it was discontinuing development of bococizumab, its PCSK9 inhibitor. According to the press release, the Company stated that: ‘The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders'. PCSK9 Forum Editors discuss the implications of this outcome, especially in the light of the recent European Society of Cardiology and European Atherosclerosis Society Consensus statement providing practical guidance for the use of PCSK9 inhibitors. Read the report » ESC/EAS Task Force consensus statement on the use of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/pubmed/27789571 New and updated edition of our popular therapeutic guide A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »   Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.